CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in mice - PubMed (original) (raw)
CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in mice
Els C M Brinkman-Van der Linden et al. Mol Cell Biol. 2003 Jun.
Abstract
Mouse CD33/Siglec-3 (mCD33) is the apparent ortholog of human CD33/Siglec-3 (hCD33), a member of the Siglec (sialic acid-binding Ig superfamily lectin) family of sialic acid-recognizing cell-surface lectins. We examined the binding specificity and expression pattern of mCD33 and explored its functions by generating mice deficient in this molecule. Like hCD33, mCD33 is expressed on myeloid precursors in the bone marrow, albeit mostly in the more mature stages of the granulocytic lineage. Moreover, unlike hCD33, mCD33 in peripheral blood is primarily expressed on granulocytes. Also, unlike hCD33, mCD33 did not bind to alpha2-3- or alpha2-6-linked sialic acids on lactosamine units. Instead, it showed distinctive sialic acid-dependent binding only to the short O-linked glycans of certain mucins and weak binding to the sialyl-Tn epitope. Binding was enhanced by removal of 9-O-acetyl groups and attenuated by truncation of the glycerol-like side chain of sialic acids. Mice deficient in CD33 were viable and fertile in a controlled-access specific-pathogen-free vivarium, showed no major morphological or histological abnormalities, had no changes in bone marrow or peripheral leukocyte subpopulations, and had very minor differences in biochemical and erythrocyte parameters. Cellular responses to intraperitoneally injected proinflammatory stimulants, as well as subsequent interleukin-6 secretion, were also apparently unaffected. These results indicate substantial species differences in CD33 expression patterns and ligand recognition and suggest functional degeneracy between mCD33 and the other CD33-related Siglec proteins expressed on cells of the myeloid lineage.
Figures
FIG. 1.
Binding of mCD33-Fc to BSM: effect of 9-O-acetylation and side chain modification of sialic acid. Biotinylated BSM was treated with base or with CHE-Fc to remove 9-O-acetyl esters from its sialic acids. ELISA was used to assay the interaction between mCD33-Fc and BSM as described in Materials and Methods. In some instances, the BSM was also treated with mild periodate to truncate sialic acid side chains. The mean _A_405 values of triplicate wells are plotted for each sample. The error bars indicate standard deviations.
FIG. 2.
CD33 expression on mouse hematopoietic cells. (A) Hematopoietic cells in bone marrow from wild-type (top panel) and CD33-deficient (bottom panel) mice were stained with the anti-CD33 antibody and analyzed by flow cytometry. The majority of Mac-1-positive cells stained weakly. (B) CD33 expression on leukocytes from various tissues. Solid bars, wild-type cells; open bars, CD33-deficient cells. MFI, median fluorescence intensity. (C) Examples of the light microscopic appearance of Giemsa-stained CD33-positive cells obtained by cell sorting from peripheral blood or bone marrow. The dominant morphology in both compartments is that of mature granulocytes.
FIG. 3.
Targeted deletion of the mCD33 gene. A CD33 gene-targeting construct was prepared by replacing the 3.8-kb DNA fragment containing exons 1 to 5 of the CD33 gene with the pPGK-neo-bpA cassette, with flanking 1.3- and 7.2-kb arms to mediate homologous recombination. A, _Apa_I; E, _Eco_RI; H, _Hin_dIII; S, _Sac_I.
Similar articles
- Cloning and characterization of a novel mouse Siglec, mSiglec-F: differential evolution of the mouse and human (CD33) Siglec-3-related gene clusters.
Angata T, Hingorani R, Varki NM, Varki A. Angata T, et al. J Biol Chem. 2001 Nov 30;276(48):45128-36. doi: 10.1074/jbc.M108573200. Epub 2001 Sep 28. J Biol Chem. 2001. PMID: 11579105 - OB-BP1/Siglec-6. a leptin- and sialic acid-binding protein of the immunoglobulin superfamily.
Patel N, Brinkman-Van der Linden EC, Altmann SW, Gish K, Balasubramanian S, Timans JC, Peterson D, Bell MP, Bazan JF, Varki A, Kastelein RA. Patel N, et al. J Biol Chem. 1999 Aug 6;274(32):22729-38. doi: 10.1074/jbc.274.32.22729. J Biol Chem. 1999. PMID: 10428856 - Sialic acid binding receptors (siglecs) expressed by macrophages.
Munday J, Floyd H, Crocker PR. Munday J, et al. J Leukoc Biol. 1999 Nov;66(5):705-11. doi: 10.1002/jlb.66.5.705. J Leukoc Biol. 1999. PMID: 10577497 Review. - Basic and clinical immunology of Siglecs.
von Gunten S, Bochner BS. von Gunten S, et al. Ann N Y Acad Sci. 2008 Nov;1143:61-82. doi: 10.1196/annals.1443.011. Ann N Y Acad Sci. 2008. PMID: 19076345 Free PMC article. Review.
Cited by
- Advances in experimental bladder models: bridging the gap between in vitro and in vivo approaches for investigating urinary tract infections.
Nissanka MC, Dilhari A, Wijesinghe GK, Weerasekera MM. Nissanka MC, et al. BMC Urol. 2024 Sep 23;24(1):206. doi: 10.1186/s12894-024-01590-w. BMC Urol. 2024. PMID: 39313789 Free PMC article. Review. - Alzheimer's disease associated isoforms of human CD33 distinctively modulate microglial cell responses in 5XFAD mice.
Eskandari-Sedighi G, Crichton M, Zia S, Gomez-Cardona E, Cortez LM, Patel ZH, Takahashi-Yamashiro K, St Laurent CD, Sidhu G, Sarkar S, Aghanya V, Sim VL, Tan Q, Julien O, Plemel JR, Macauley MS. Eskandari-Sedighi G, et al. Mol Neurodegener. 2024 May 27;19(1):42. doi: 10.1186/s13024-024-00734-8. Mol Neurodegener. 2024. PMID: 38802940 Free PMC article. - Comparison of Siglec-1 protein networks and expression patterns in sperm and male reproductive tracts of mice, rats, and humans.
Almhanna H, Kumar AH, Kilroy D, Duggan G, Irwin JA, Hogg B, Reid C. Almhanna H, et al. Vet World. 2024 Mar;17(3):645-657. doi: 10.14202/vetworld.2024.645-657. Epub 2024 Mar 21. Vet World. 2024. PMID: 38680147 Free PMC article. - Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity.
Lydeard JR, Lin MI, Ge HG, Halfond A, Wang S, Jones MB, Etchin J, Angelini G, Xavier-Ferrucio J, Lisle J, Salvadore K, Keschner Y, Mager H, Scherer J, Hu J, Mukherjee S, Chakraborty T. Lydeard JR, et al. Mol Ther Methods Clin Dev. 2023 Oct 13;31:101135. doi: 10.1016/j.omtm.2023.101135. eCollection 2023 Dec 14. Mol Ther Methods Clin Dev. 2023. PMID: 38027064 Free PMC article. - Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy.
Yu Y, Peng W. Yu Y, et al. Cancer Biol Med. 2023 May 3;20(5):369-84. doi: 10.20892/j.issn.2095-3941.2023.0046. Cancer Biol Med. 2023. PMID: 37133224 Free PMC article. Review.
References
- Angata, T., and E. Brinkman-Van der Linden. 2002. I-type lectins. Biochim. Biophys. Acta 1572:294-316. - PubMed
- Angata, T., R. Hingorani, N. M. Varki, and A. Varki. 2001. Cloning and characterization of a novel mouse Siglec, mSiglec-F: differential evolution of the mouse and human (CD33) Siglec-3-related gene clusters. J. Biol. Chem. 276:45128-45136. - PubMed
- Angata, T., and A. Varki. 2000. Siglec-7: a sialic acid-binding lectin of the immunoglobulin superfamily. Glycobiology 10:431-438. - PubMed
- Angata, T., and A. Varki. 2000. Cloning, characterization, and phylogenetic analysis of Siglec-9, a new member of the CD33-related group of Siglecs—evidence for co-evolution with sialic acid synthesis pathways. J. Biol. Chem. 275:22127-22135. - PubMed
- Angata, T., and A. Varki. 2002. Chemical diversity in the sialic acids and related alpha-keto acids: an evolutionary perspective. Chem. Rev. 102:439-470. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous